CClinicalTrials.gg
RecruitingNCT03291392Updated Feb 24, 2026

CUHK Stroke Biobank

An observational study in Stroke, Ischemic, Genetic Disease and Atherosclerosis, Cerebral, sponsored by Chinese University of Hong Kong. Recruiting at 1 site in Hong Kong. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-24.

Sponsored by Chinese University of Hong Kong · Observational

Study type
Observational
Model
Other
Time perspective
Other
Enrollment
500
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of the study are:

  1. To make quality, characterized samples and related data available for future studies, including Genome Wide Association Studies (GWAS), genomics, and biomarker research;
  2. To use these samples and related medical information to answer research questions aimed at understanding the genetics and underlying biology of acquired disease and injury to the brain, heart and blood vessels with the express purpose of advancing the search for effective modalities for prevention, treatment, and recovery;
  3. To develop additional operational infrastructure to support this project across the Prince of Wales Hospital and divisions, including (1) tracking of patient consent, (2) management of collection and sample processing processes, (3) sample inventory and QC/QA processes, and (4) release of materials to investigators for further research.
Read the detailed description

TYPES OF TISSUES TO BE BANKED

Blood:

Blood will be collected from the out-patient clinic, prospectively at the time of a clinically planned procedure or prospectively during a procedure performed solely for research. After informed consent is obtained, the patient/ subject will be asked to donate a one-time blood sample of up to 30ml. A portion of each blood sample will be used to generate a DNA sample, and the remainder will be used to separate out plasma, peripheral blood cells, and/or serum for future research studies, including but not limited to metabolomics, proteomics, biomarker measurements, and bioenergetic assays.

Cerebrospinal Fluid:

Cerebrospinal fluid 5-10ml may be collected prospectively from lumbar puncture or the subset of patients who have an external ventricular drain (EVD) placed as part of their clinical care. The standard clinical protocol for EVD includes the drainage of CSF externally into a collection bag. Once the volume of CSF drainage is recorded, the CSF is typically discarded. The collection of CSF will be coordinated with the subject's primary treatment team. At this time, CSF banking will not occur in subjects who do not have CSF collection planned as part of their clinical care.

Body Tissue:

The body tissue will be collected from the patients who undergo the carotid stent which is their routine medical treatment. Around 5mg tissue will be taken from the filter wire during the stenting operation and then stabilized by RNAlater reagent immediately. The tissue will be kept in -80oC freezer for future process.

Buccal swab or saliva:

Buccal swab or saliva (\~5-10ml) may be collected from the patients, their family members and/or normal subjects for DNA and RNA extraction if necessary. It would be collected by the trained doctor, medical staffs or research assistant. The collected samples will be kept in -80oC freezer for future use, for example, extraction of DNA.

02

Conditions studied

  • Stroke, Ischemic
  • Genetic Disease
  • Atherosclerosis, Cerebral

Keywords

  • Genetics
  • Stroke
  • Biobank
  • Atherosclerosis
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

  1. Chinese ONLY
  2. Patients with intracranial stenosis or extracranial stenosis equal to or >70%
  3. Stroke patients and their family members
  4. Normal subject without any intracranial stenosis/ extracranial stenosis

Inclusion criteria

  1. Adult equal or more 18 years of age and Chinese ONLY.
  2. Stroke patients, their family members, and/or the normal subjects without intracranial stenosis or extracranial stenosis, are eligible to join the study.
  3. Subject is willing to have blood taken, cerebral spinal fluid and/or body tissue drawn for storage in the research bank.

Exclusion criteria

Exclusion Criteria:

  • None
04

Study design

Observational model
Other
Time perspective
Other
Enrollment
500 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Atherosclerosis

    Patient with intracranial stenosis or extracranial stenosis equal to or more than 70% would be invited to join the study for blood taking. Biobank: Gene expression or biomarkers exploration for atherosclerotic-related genetic diseases

    Genetic: Gene expression or biomarkers exploration

  • Family members

    The stroke patient who had family history of stroke, their parents and siblings would also be invited to join the study for blood taking or buccal swab/ saliva collection. Biobank: Gene expression or biomarkers exploration for atherosclerotic-related genetic diseases

    Genetic: Gene expression or biomarkers exploration

  • Normal subjects

    Normal subjects without ischemic stroke or intracranial/extracranial stenosis would be invited to join the study for blood taking. Biobank: Gene expression or biomarkers exploration for atherosclerotic-related genetic diseases

    Genetic: Gene expression or biomarkers exploration

Interventions

  • GeneticGene expression or biomarkers exploration
05

What researchers measure

Primary outcomes

  1. Ischemic stroke-related genetics

    1. Discovery of novel genetic predictor of stroke and its complications will be done by identifying cases and controls for different stroke subtype and complications within the recruited samples, and using whole-genome genotyping arrays, or by sequencing approaches. 2. Replication of novel genetic markers of stroke will be performed using a combination of genotyping, multiplex genotyping, customized-content genotyping arrays and sequencing.

    Time frame: Dec, 2025

06

Study locations

1 of 1 sites recruiting
  • Chinese University of Hong Kong
    Hong Kong, Hong Kong
    Recruiting
07

References and documents

Individual participant data

Plan to share: Undecided — Tissues and data from the repository will only be shared with other academic, non-profit institutions. No collaboration with for-profit companies is anticipated. All investigators seeking to gain access to the repository must first demonstrate that their research interests are relevant to the central theme of the repository. Investigators must also complete all required IRB documentation before samples and information will be released. In the event that a commercial, for-profit, collaboration is sought, a bona fide intellectual collaboration between the PI and an individual or group at the for-profit site and a Materials Transfer Agreement will be required. For all researchers requesting samples, the IRB recommended Letter of Agreement must be signed prior to our releasing tissues and information.

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03291392
Lead sponsor
Chinese University of Hong Kong
Responsible party
Leung Wai Hong Thomas (Professor, Chinese University of Hong Kong) — Principal investigator
First posted
Sep 25, 2017
Start date
Jun 15, 2015
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Feb 24, 2026

Study contacts

Thomas Wai Hong LEUNG, FRCP
Contact
drtleung@cuhk.edu.hk
852-35053593
Thomas Wai Hong LEUNG, FRCP
principal investigator · Chinese University of Hong Kong

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion